Journal of Animal Reproduction and Biotechnology (한국동물생명공학회지)

The Korean Society of Animal Reproduction and Biotechnology (한국동물생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Side effects of treatment with busulfan at high doses in dogs

  • Hur, Tai-Young (Department of Animal Diseases & health, National Institute of Animal Science, RDA) ;
  • Lee, Seunghoon (Animal Biotechnology Division, National Institute of Animal Science, RDA) ;
  • Ock, Sun-A (Animal Biotechnology Division, National Institute of Animal Science, RDA) ;
  • Jhun, Hyunjhung (Research Group of Nutraceuticals for Metabolic Syndrome, Korea Food Research Institute) ;
  • Lee, Won-Young (Department of Animal Science, Korea National University of Agricultures and Fisheries)
  • Received : 2022.05.16
  • Accepted : 2022.06.08
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Busulfan is the most commonly used drug for preconditioning during the transplantation of hematopoietic stem cells and male germ cells. Here, we describe side effects of high doses of busulfan in male mongrel dogs. Busulfan was intravenously administered to three groups of dogs at doses of 10, 15, and 17.5 mg/kg body weight. The total white blood cell, neutrophil, eosinophil, lymphocyte, monocyte, and platelet counts steadily reduced in a dose-dependent manner following busulfan treatment. The white blood cell, neutrophil, and monocyte counts recovered after 6 weeks of busulfan treatment, however, the eosinophil, lymphocyte, and platelet counts remained unaltered. Additionally, there was one fatality in the each of the groups that were administered 15 and 17.5 mg/kg busulfan. The gross lesions included severe hemorrhage in the stomach, intestinal tracts, mesentery and urinary bladder. Microscopic investigation revealed severe pulmonary edema and hemorrhage in the lungs, and severe multifocal to coalescing transmural hemorrhage in the intestines and urinary bladder. These results indicated that treatment with busulfan at doses higher than 15 mg/kg initiates severe bleeding in the internal organs and can have fatal results.

Keywords

Acknowledgement

We thank Dr. Soyoung Chun for caring and treating experimetal dogs.

References

  1. Abe T, Kono S, Ohnuki T, Hishikawa S, Kunita S, Hanazono Y. 2016. A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan. Exp. Anim. 65: 345-351. https://doi.org/10.1538/expanim.16-0022
  2. Bucci LR and Meistrich ML. 1987. Effects of busulfan on murine spermatogenesis: cytotoxicity, sterility, sperm abnormalities, and dominant lethal mutations. Mutat. Res. 176:259-268. https://doi.org/10.1016/0027-5107(87)90057-1
  3. Deeg HJ, Schuler US, Shulman H, Ehrsam M, Renner U, Yu C, Storb R, Ehninger G. 1999. Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model. Biol. Blood Marrow Transplant. 5:316-321. https://doi.org/10.1016/S1083-8791(99)70007-8
  4. Hayakawa J, Hsieh MM, Uchida N, Phang O, Tisdale JF. 2009. Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice. Stem Cells 27:175-182. https://doi.org/10.1634/stemcells.2008-0583
  5. Hermann BP, Sukhwani M, Winkler F, Pascarella JN, Peters KA, Sheng Y, Valli H, Rodriguez M, Ezzelarab M, Dargo G, Peterson K, Masterson K, Ramsey C, Ward T, Lienesch M, Volk A, Cooper DK, Thomson AW, Kiss JE, Penedo MC, Schatten GP, Mitalipov S, Orwig KE. 2012. Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell 11:715-726. https://doi.org/10.1016/j.stem.2012.07.017
  6. Hur TY, Lee SH, Ock SA, Song H, Park HJ, Lee R, Sung SH, Jhun H, Lee WY. 2017. Dose-dependent effects of busulfan on dog testes in preparation for spermatogonial stem cell transplantation. Lab. Anim. Res. 33:264-269. https://doi.org/10.5625/lar.2017.33.3.264
  7. Kim JH, Jung-Ha HS, Lee HT, Chung KS. 1997. Development of a positive method for male stem cell-mediated gene transfer in mouse and pig. Mol. Reprod. Dev. 46:515-526. https://doi.org/10.1002/(SICI)1098-2795(199704)46:4<515::AID-MRD10>3.0.CO;2-V
  8. Kim YM, Park KJ, Park JS, Jung KM, Han JY. 2021. In vivo enrichment of busulfan-resistant germ cells for efficient production of transgenic avian models. Sci. Rep. 11:9127. https://doi.org/10.1038/s41598-021-88706-6
  9. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. 2008. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr. Drug Saf. 3:60-66. https://doi.org/10.2174/157488608783333899
  10. McCune JS and Holmberg LA. 2009. Busulfan in hematopoietic stem cell transplant setting. Expert Opin. Drug Metab. Toxicol. 5:957-969. https://doi.org/10.1517/17425250903107764
  11. Ogawa T, Dobrinski I, Brinster RL. 1999. Recipient preparation is critical for spermatogonial transplantation in the rat. Tissue Cell 31:461-472. https://doi.org/10.1054/tice.1999.0060
  12. Perdomo J, Yan F, Leung HHL, Chong BH. 2017. Megakaryocyte differentiation and platelet formation from human cord blood-derived CD34+ cells. J. Vis. Exp. (130):56420.
  13. Stellflug JN, Green JS, Leathers CW. 1985. Antifertility effect of busulfan and procarbazine in male and female coyotes. Biol. Reprod. 33:1237-1243. https://doi.org/10.1095/biolreprod33.5.1237
  14. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED. 1977. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation 24:349-357. https://doi.org/10.1097/00007890-197711000-00006
  15. Xie Y, Deng CC, Ouyang B, Lv LY, Yao JH, Zhang C, Chen HC, Li XY, Sun XZ, Deng CH, Liu GH. 2020. Establishing a nonlethal and efficient mouse model of male gonadotoxicity by intraperitoneal busulfan injection. Asian J. Androl. 22:184-191. https://doi.org/10.4103/aja.aja_41_19
  16. Zahorec R. 2001. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl. Lek. Listy 102:5-14.